letrozole

Org: Gustave Roussy Cancer Center, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino Genoa,

Abstract

Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).

Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,

Abstract

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

Org: Centro Oncologico International,

Abstract

Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.

Org: Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, Austrian Breast and Colorectal Cancer Study Group, Wien, Austria, Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Vienna, Austria, Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria,

Abstract

A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.

Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,

Abstract

I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).

Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,

Abstract

Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.

Org: Seoul National University Hospital, Seoul National University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul National University Bundang Hospital,

Abstract

LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.

Org: Genor Biopharma Co.,Ltd., Genor Biopharma, Genor Biopharma Co.,Ltd., Shanghai, China, Genor Biopharma Co., Ltd., Beijing, China,

Abstract

Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.

Org: Spanish Breast Cancer Group, Málaga,

Abstract

Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study.

Org: Georgetown University Medical Center, Washington, DC, Tufts Medical Center/Tufts University, Boston, MA, National Cancer Institute/National Institutes of Health,

Abstract

Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.

Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,

Abstract

Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.

Org: Xin Hua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine,

Abstract

AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,

Abstract

Neoadjuvant aromatase inhibitor therapy for ER+ breast cancer: The NAOMI trial.

Org: Dartmouth-Hitchcock Medical Center, Dartmouth College Geisel School of Medicine, Medical College of Wisconsin,

Abstract

A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer.

Org: Winthrop P. Rockefeller Cancer Institute, Women's Cancer Center of Nevada,

Abstract

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.

Org: UCLA Santa Monica Hematology/Oncology Regulatory-2, Novartis Healthcare Private Limited, Novartis Ireland,

Abstract

Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor–positive, early breast cancer in India.

Org: Department of Medical Oncology, BRA-IRCH,

Abstract

GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma.

Org: Gynecologic Oncology Group Statistical and Data Center, Mount Pleasant, SC, Texas Oncology and Gynecologic Oncology Group (GOG) Foundation, Shenandoah, TX, GOG and Gynecologic Oncology,

Abstract

Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study.

Org: Genecast Precision Medical Diagnostic Laboratory, Wuxi Co., Ltd, Wuxi, China,

Abstract

Efficacy, safety, and predictive biomarkers of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer: A phase II study.

Abstract

Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.

Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, France,

Abstract

Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors.

Org: Hiroshima Prefectural Hospital, Hiroshima City North Medical Center Asa Citizens Hospital, JA Onomichi General Hospital, JA Hiroshima General Hospital,

Abstract

The impact of cannabidiol (CBD) on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Org: University of Michigan Health Management Research Center,

Clinical trial

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-04-30

Clinical trial

Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function

Status: Completed, Estimated PCD: 2013-06-13

Clinical trial

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Clinical trial

A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)

Status: Completed, Estimated PCD: 2015-12-21

Clinical trial

Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2024-08-01

Clinical trial

Prospective Pilot Study to Determine the Effect of Aromatase Inhibitor-induced Estrogen Depletion on Evoked Pain Threshold and Psychosocial Factors in Breast Cancer Patients

Status: Completed, Estimated PCD: 2012-07-01

Clinical trial

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Status: Recruiting, Estimated PCD: 2028-09-01

Clinical trial

Clinical Effect Analysis of Different Regimens of Capecitabine in the Treatment of Patients With Advanced Colon Cancer

Status: Completed, Estimated PCD: 2023-12-31

Clinical trial

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Status: Active (not recruiting), Estimated PCD: 2021-05-26

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-10-25

Abstract

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Pfizer, Inc.,

Abstract

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.

Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,

Abstract

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Org: Kent Oncology Centre, Istituto Europeo Oncologico, Hôpital Européen Georges Pompidou, Medica Scientia Innovation Research (MEDSIR), Pangaea Oncology,

Abstract

A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.

Org: Hospital São Lucas da PUCRS, Hospital Fêmina - Grupo Hospitalar Conceição, Brazilian Gynecologic Oncology Group (EVA), Latin American Cooperative Oncology Group (LACOG), Division of Clinical Research and Technological Development - Brazilian National Cancer Institute (INCA),

Abstract

Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.

Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, Section of Urology, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University of Chicago Department of Urology,

Abstract

Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.

Org: University Hospitals, Leuven, Belgium, Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain, Institut Curie, PSL Research University, Saint-Cloud, France, Hospital Virgen del Rocio de Sevilla, Seville, Spain, Memorial Sloan Kettering Cancer Center, New York, NY, USA,

Abstract

PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).

Org: Fudan University Shanghai Cancer Center, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Breast Oncology, Peking University Cancer Hospital, Harbin Medical University Cancer Hospital,

Abstract

Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.

Org: Helios Klinikum Berlin-Buch, Dana-Farber Cancer Institute, International Breast Cancer Center, Quiron Group, Practice for Hematology and Internal Oncology, Latin American Cooperative Oncology Group (LACOG),

Abstract

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,

Abstract

Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.

Org: School of Medicine University of Zagreb, Agency for Medicinal Products and Medical Devices of Croatia, University Hospital Centre Zagreb, General Hospital Sibenik, General Hospital Šibenik,

Abstract

ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.

Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,

Abstract

lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).

Org: NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany, Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA,

Abstract

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.

Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,

Abstract

The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The Breast Cancer Endocrine Therapy Fitness (BE-FIT) randomized controlled trial.

Org: University of British Columbia, BC Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency, University of Toronto,

Abstract

Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study.

Org: Daiichi Sankyo Inc., Basking Ridge, NJ, NJ, Cardinal Health, Dublin, Ireland,

Abstract

Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study.

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, University of Pittsburgh Medical Center, Endocrinology and metabolic institute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Symptom burden of patients with breast cancer on adjuvant hormone therapy: A preliminary report.

Org: Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University, Fox Chase Cancer Center,

Abstract

Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.

Org: Jiangsu Hengrui Pharmaceuticals Co.,Ltd,

Abstract

Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.

Org: National and Kapodistrian University of Athens, Alexandra University Hospital,

Abstract

The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3.

Org: University of Virginia Health System, Duke University Medical Center / Duke Cancer Institute, University of Virginia, Charlottesville, VA, USA,

Abstract

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.

Org: EHC, Morges, Switzerland, University Hospital 12 de Octubre, Institut Curie, Saint Cloud, France, Centre GF Leclercq,

Abstract

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.

Org: Fondazione IRCCS San Gerardo dei Tintori, Clinical Cancer Centre, IRCCS-AUSL di Reggio Emilia, Ospedale Civile Guastalla, Hospital Piacenza,

Abstract

Malignancy in patients with sickle cell disease: A single center experience.

Org: Louisiana State University Shreveport, Louisiana State University Health Sciences Center - Shreveport, LSU Health Shreveport, LSU Health Sciences Center, Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA,

Product

Adjuvant endocrine therapy

Product

ribociclib and letrozole

Product

Anlotinib + Letrozole

Product

Letrozole + Palbociclib

Clinical trial

A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.

Status: Completed, Estimated PCD: 2012-04-04

Clinical trial

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Status: Not yet recruiting, Estimated PCD: 2025-10-15